Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA, Everyday Health join forces

This article was originally published in The Tan Sheet

Executive Summary

The agency's collaboration with consumer health information network Everyday Health will allow FDA's food and medical product safety alerts and postings about wellness and prevention to reach Everyday Health's 30 million unique monthly visitors. The Web site's owner, Waterfront Media, and FDA launched the co-branded portal 1www.EverydayHealth.com/FDA, and will jointly publish a weekly newsletter on drug safety, children's health products and cosmetics, according to a Nov. 17 release. FDA also works with WebMD to communicate with consumers (2"The Tan Sheet" Nov. 2, 2009, In Brief)

You may also be interested in...



FDA partners with Drugs.com

Drugs.com will provide visitors FDA consumer updates through a partnership announced May 26. The arrangement will enhance FDA's "effort to ensure the public has easy access to reliable, useful information that can help people protect and improve their health," the agency says. FDA also partners with WebMD and Everyday Health to bolster consumer outreach (1"The Tan Sheet" Nov. 30, 2009, In Brief)

FDA, WebMD expand partnership

FDA and WebMD Health Corp. expand their partnership to provide consumers with increased access to FDA's consumer information, the agency says Oct. 29. The second phase of the partnership launched in December 2008 includes additional multimedia tools and content on WebMD's Web site about allergies and asthma, children's health, diabetes, heart health and vitamins and supplements, FDA says. A release says the partnership increased FDA's consumer reach when the agency warned the public to stop using Iovate Pharmaceuticals' weight-loss product Hydroxycut because of serious adverse event reports (1"Health News Daily" May 4, 2009)

Neuroscience Challenges Oncology For Top Spot In CDER’s 2019 Novel Approvals

Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.

Topics

UsernamePublicRestriction

Register

PS103567

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel